

COVID-19 pandemic impact on cytopathology practice in the post-lockdown period: An international, multicenter study

Elena Vigliar, MD, PhD¹; Pasquale Pisapia, MD ¹; Filippo Dello Iacovo, MD²; Eduardo Alcaraz-Mateos, MD, PhD³; Greta Ali, MD, PhD⁴; Syed Z. Ali, MD⁵; Zubair W. Baloch, MD⁶; Claudio Bellevedere, MD, PhD ¹; Massimo Bongiovanni, MD ⁷; Pavlina Botsun, MD⁸; Dario Bruzzese, PhD¹; Lukas Bubendorf, MD ⁹; Reinhard Büttner, MD, PhD¹⁰; Sule Canberk, MD ¹¹; Arrigo Capitanio, MD¹²; Chiara Casadio, MD¹³; Eugeniu Cazacu, MD¹⁴; Beatrix Cochand-Priollet, MD, PhD¹⁵; Alessandro D'Amuri, MD, PhD¹⁶; Katelynn Davis, MD⁵; Catarina Eloy, MD, PhD ¹¹; Marianne Engels, MD¹⁰; Guido Fadda, MD¹⁷; Gabriella Fontanini, MD⁴; Franco Fulciniti, MD, PhD¹⁸; Paul Hofman, MD, PhD ¹⁹; Antonino Iaccarino, PhD¹; Antonio Ieni, MD, PhD¹⁷; Xiaoyin Sara Jiang, MD ²⁰; Kennichi Kakudo, MD, PhD ²¹; Izidor Kern, MD²²; Ivana Kholova, MD, PhD²³; Kathryn M. Linton McDermott, MD²⁴; Chinhua Liu, CT²⁵; Anandi Lobo, MD²⁶; Maria D. Lozano, MD, PhD ²⁷; Umberto Malapelle, PhD¹; Zahra Maleki, MD ⁵; Pamela Michelow, MD²⁸; Michael W. Mikula, MD⁵; Jamal Musayev, MD²⁹; Gonca Özgün, MD³⁰; Meltem Oznur, MD³¹; Francisca Maria Peiró Marqués, MD³²; David Poller, MD²⁴; Michal Pyzlak, MD, PhD³³; Betsy Robinson, CT²⁰; Esther Diana Rossi, MD, PhD ³⁴; Sinchita Roy-Chowdhuri, MD, PhD ²⁵; Mauro Saieg, MD, PhD ³⁵; Spasenija Savic Prince, MD⁹; Fernando C. Schmitt, MD, PhD¹¹; Francisco Javier Seguí Iváñez, MD³²; Tajana Štoos-Veić, MD, PhD³⁶; Oksana Sulaieva, MD, PhD⁸; Brenda J. Sweeney, MD³⁷; Giovanni Tuccari, MD¹⁷; Marie-Louise van Velthuysen, MD, PhD³⁸; Paul A. VanderLaan, MD, PhD ³⁹; Philippe Vielh, MD, PhD⁴⁰; Patrizia Viola, MD⁴¹; Quirinus J. M. Voorham, PhD⁴²; Birgit Weynand, MD⁴³; Pio Zeppa, MD, PhD ⁴⁴; William C. Faquin, MD, PhD ³⁷; Martha Bishop Pitman, MD³⁷; and Giancarlo Troncone, MD, PhD ¹

Corresponding Author: Giancarlo Troncone, MD, PhD, Department of Public Health, University of Naples Federico II, Via Sergio Pansini 5, 80131 Naples, Italy (giancarlo.troncone@unina.it).

¹Department of Public Health, University of Naples Federico II, Naples, Italy; ²Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy; ³Pathology Department, Jose M. Morales Meseguer University General Hospital, Murcia, Spain; ⁴Department of Surgical, Medical, and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy; ⁵Division of Cytopathology, Department of Pathology, Johns Hopkins Hospital, Baltimore, Maryland; ⁶Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania; ⁷Cytopathology, SYNLAB Suisse SA, Lausanne, Switzerland; ⁸Anatomic Pathology, Laboratory of Pathology CSD, Kiev, Ukraine; ⁹Institute of Pathology, University Hospital Basel, Basel, Switzerland; ¹⁰Department of Pathology, University Hospital Cologne, Cologne, Germany; ¹¹Medical Faculty, Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal; ¹²Department of Pathology, Linköping University Hospital, Linköping, Sweden; ¹³Division of Diagnostic Cytopathology, European Institute of Oncology IRCCS, Milan, Italy; ¹⁴Department of Morphopathology, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova; ¹⁵Department of Pathology, Cochin Hospital, Assistance Publique – Hôpitaux de Paris (APHP), University of Paris, Paris, France; ¹⁶Anatomic Pathology Unit, A. Perrino Hospital, Azienda Sanitaria Locale (ASL) Brindisi, Brindisi, Italy; ¹⁷Section of Pathological Anatomy, Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, G. Martino Hospital, Messina, Italy; ¹⁸Clinical Cytopathology Service, Histopathology Service, Cantonal Institute of Pathology, Locarno Cantonal Hospital, Locarno, Switzerland; ¹⁹Laboratory of Clinical and Experimental Pathology, Hospital-Related Biobank (BB-0033-00,025), FHU OncoAge, Pasteur Hospital, Nice, France; ²⁰Department of Pathology, Duke University Medical Center, Durham, North Carolina; ²¹Department of Pathology, Izumi City General Hospital, Izumi, Japan; ²²Department of Pathology, University Clinic Golnik, Golnik, Slovenia; ²³Department of Pathology, Fimlab Laboratories, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; ²⁴Department of Pathology and Cytology, Queen Alexandra Hospital, Portsmouth, United Kingdom; ²⁵Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; ²⁶Department of Pathology, Kapoor Path Laboratories, Raipur, India; ²⁷Department of Pathology, University Clinic of Navarra, Pamplona, Spain; ²⁸Department of Anatomical Pathology, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa; ²⁹Department of Pathology, Baku Pathology Center, Baku, Azerbaijan; ³⁰Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey; ³¹Department of Pathology, Tekirdag Namik Kemal University, Suleymanpaşa/Tekirdag, Turkey; ³²Department of Pathology, General University Hospital of Alicante, Alicante, Spain; ³³Anatomic Pathology, Center for Diagnostic Pathology, Warsaw, Poland; ³⁴Division of Anatomical Pathology and Histology, Catholic University of Sacred Heart–University Polyclinic Foundation “A. Gemelli”, Rome, Italy; ³⁵Department of Pathology, A. C. Camargo Cancer Center, Santa Casa Medical School, Sao Paulo, Brazil; ³⁶Department of Pathology and Cytology, University Hospital Dubrava, Zagreb, Croatia; ³⁷Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; ³⁸Department of Pathology, Erasmus Medical Centre, Rotterdam, the Netherlands; ³⁹Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; ⁴⁰Medipath, American Hospital of Paris, Paris, France; ⁴¹North West London Pathology, Imperial College Healthcare, National Health Service Trust Charing Cross Hospital, London, United Kingdom; ⁴²Anatomic Pathology, Pathological Anatomical National Automated Archive (PALGA) Foundation, Houten, the Netherlands; ⁴³Department of Pathology, University Hospitals Leuven, Leuven, Belgium; ⁴⁴Department of Medicine and Surgery, University of Salerno, Fisciano, Italy

The last 3 authors contributed equally to this article.

Received: September 2, 2021; **Revised:** November 15, 2021; **Accepted:** November 16, 2021

Published online January 10, 2022 in Wiley Online Library (wileyonlinelibrary.com)

DOI: 10.1002/cncy.22547, wileyonlinelibrary.com

BACKGROUND: In a previous worldwide survey, the authors showed a drastic reduction in the number of cytological specimens processed during the coronavirus disease 2019 “lockdown” period along with an increase in malignancy rates. To assess the continued impact of the pandemic on cytological practices around the world, they undertook a second follow-up worldwide survey collecting data from the post-lockdown period (2020). **METHODS:** Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post-lockdown period (2020), which ranged from April 4 to October 31. Differences between the post-lockdown period and the corresponding 2019 period were evaluated, and the authors specifically focused on rates of malignant diagnoses. **RESULTS:** A total of 29 respondents from 17 countries worldwide joined the survey. Overall, a lower number of cytological specimens ($n = 236,352$) were processed in comparison with the same period in 2019 ($n = 321,466$) for a relative reduction of 26.5%. The overall malignancy rate showed a statistically significant increase (12,442 [5.26%] vs 12,882 [4.01%]; $P < .001$) during the same time period. Similar results were obtained if both malignancy and suspicious for malignancy rates were considered together (15,759 [6.58%] vs 16,011 [4.98%]; $P < .001$). **CONCLUSIONS:** The data showed a persistent reduction in the cytological specimen volume during the post-lockdown period (2020). However, the relative increase in the cytological workload in the late part of the post-lockdown is a promising finding of a slow return to normality. *Cancer Cytopathol* 2022;130:344-351. © 2022 American Cancer Society.

KEY WORDS: cancer screening program; coronavirus disease 2019 (COVID-19); cytopathology; fine-needle aspiration; malignancy rate.

INTRODUCTION

The end of 2019 was characterized by the rise of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2.¹⁻³ The pandemic status was officially declared by the World Health Organization on March 11, 2020.⁴ At the time of this writing (July 2021), more than 185 million people had been reported to be test-positive, with more than 4 million deaths worldwide.⁵

The COVID-19 pandemic has significantly affected medical and laboratory practices around the world, including cytopathology practices.⁶⁻⁹ In fact, to “flatten the curve,” governments worldwide have imposed severe countermeasures limiting freedom of movement and everyday activities to reduce the spread of the disease. A major consequence of these limitations is the postponement of “nonurgent” medical and elective surgical procedures, which has resulted in a significant reduction in the activity of cytopathology services.⁸⁻¹² For example, in our previous survey of 41 laboratories from 23 different countries, there was a drastic reduction in the number of cytological specimens processed during the “lockdown” period along with a higher malignancy rate in comparison with the pre-lockdown period because of the prioritization of cytological specimens from individuals with a high cancer risk.⁸

The post-lockdown period in the second part of 2020 saw less restrictive measures. All medical services, including cytopathology, increased their services but still experienced a reduction in cytological specimens with respect to the corresponding prepandemic period and continued to see a persistently higher malignancy rate.^{13,14} However, these data reflect only a single institution’s experience, and global data regarding cytological practices

in the post-lockdown period are limited. To fill this knowledge gap, a worldwide survey was taken to investigate the state of cytopathology laboratories during the COVID-19 pandemic post-lockdown period (2020).

MATERIALS AND METHODS

In this study, we applied the same methodology followed in our previous survey.⁸ Briefly, an Excel questionnaire template was sent via email to the cytopathologists who had participated in the previous survey; these included the CytoESP Working Group (cytopathologists from the European Society of Pathology; <https://www.esp-pathology.org/working-groups/esp-working-groups/cytopathology.html>) and the cytopathologists who had participated in at least 1 of the 9 Annual National Molecular Cytopathology meetings in Naples, Italy (<https://www.molecularcytopathology.com/>), regardless of the single-participant sample workload. Only a single invitation email with no subsequent reminders was sent. Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post-lockdown period and to stratify the data by consecutive 3-week intervals. The study period was individualized for each institution because of the variability of lockdowns among countries. In countries in which a lockdown did not take place, cytopathologists were asked to provide data from the first 12 weeks after the peak infection spread. Only data obtained from laboratories that had participated in both surveys were compared with those reported in the corresponding baseline period in 2019. Questions included in the survey are listed in Figure 1. All information regarding human material was managed with anonymous numerical codes, and all samples were handled in compliance with the

Declaration of Helsinki. The data were grouped into four 3-week periods, as previously reported.¹³ Briefly, the overall workload rates for each specimen type were compared, and the total number of processed samples was recorded. Moreover, as far as the distribution of diagnostic classes was concerned, the numbers of suspicious and malignant non-gynecological diagnoses were compiled.

Differences between the post-lockdown period (2020) and the corresponding 2019 period were evaluated on the basis of absolute numbers. Differences in the rates of malignant diagnoses were assessed via the χ^2 test; *P* values lower than .05 were deemed to be statistically significant.

RESULTS

A total of 29 respondents from 17 countries worldwide (Azerbaijan [1 respondent], Belgium [1 respondent], Croatia [1 respondent], France [1 respondent], Finland [1 respondent], Germany [1 respondent], Italy [6 respondents, including previously reported data¹³], Japan [1 respondent], Moldova [1 respondent], Netherlands [1 respondent], Portugal [1 respondent], Spain [2 respondents], Slovenia [1 respondent], Turkey [2 respondents], Ukraine [1 respondent], the United Kingdom [2 respondents], and the United States [5 respondents]) joined the survey. For the most part, the data reflected single-institution activity except in 1 instance in which

multi-institutional data were provided (Pathological National Automated Archive Public Pathology Database of the Netherlands; <https://www.palga.nl/en/public-database.html>). Because the timing of COVID-19 lockdowns differed among countries, each institution selected its most representative first 12 weeks of post-lockdown practice between April 4 and October 31, 2020.

Overall, a lower number of cytological specimens (*n* = 236,352) were processed during the post-lockdown period (2020) with respect to the same period in 2019 (*n* = 321,466) for a reduction of 26.5% (Table 1). The reduction was significant in each of the consecutive 3-week periods (period I, 49,724 vs 82,720; -39.9%; period II, 60,882 vs 88,744; -31.4%; period III, 60,715 vs 77,917; -22.1%; period IV, 65,031 vs 72,085; -9.8%; Table 2), although there was a trend toward a return to baseline volumes. Overall, the greatest reductions in the number of processed samples were observed for thyroid (-32.8%), cervical-vaginal tract (-30.7%), breast (-20.8%), serous cavity (-16.8%), salivary gland (-14.4%), respiratory tract (-12.2%), urine (-10.5%), and lymph node specimens (-7.5%); only 4 sample categories (central nervous system, gastrointestinal tract, biliary tract, and bone marrow specimens) showed an increase in the number of processed cytological samples (Table 3).

The overall malignancy rate of all samples obtained during the study period showed a statistically significant

COVID-19 POST-LOCKDOWN PERIOD					CORRESPONDING PERIODS IN 2019				
n°					n°				
Total number of cytological samples - 12 weeks					Total number of cytological samples - 12 weeks				
Different sample sites (n°)	post-lockdown weeks n° 1-2-3	post-lockdown weeks n° 4-5-6	post-lockdown weeks n° 7-8-9	post-lockdown weeks n° 10-11-12	Different sample sites (n°)	weeks n° 1-2-3	weeks n° 4-5-6	weeks n° 7-8-9	weeks n° 10-11-12
Cervicovaginal tract					Cervicovaginal tract				
Urinary tract					Urinary tract				
Serous cavities					Serous cavities				
Breast					Breast				
Lymph node					Lymph node				
Thyroid					Thyroid				
Respiratory tract					Respiratory tract				
Salivary gland					Salivary gland				
Soft tissue					Soft tissue				
Central nervous system					Central nervous system				
Gastrointestinal tract					Gastrointestinal tract				
Pancreas					Pancreas				
Liver					Liver				
Biliary tract					Biliary tract				
Anal-rectal region					Anal-rectal region				
Bone marrow					Bone marrow				
Other sites					Other sites				
Number of malignant diagnoses					Number of malignant diagnoses				
Number of suspicious for malignancy diagnoses					Number of suspicious for malignancy diagnoses				

Figure 1. Survey questions. Participants were asked to provide data regarding their cytopathology activity during the first 12 weeks of their respective national post-lockdown period, with the data stratified by consecutive 3-week intervals. COVID-19 indicates coronavirus disease 2019.

TABLE 1. Total Numbers of Cytological Samples During 12 Weeks of the Post-Lockdown Period and the Corresponding Period in 2019 for Each Respondent

Respondent	Post-Lockdown Period (2020), N°.	Corresponding Period (2019), N°.	Difference, %	Difference Observed During Emergency Period (Lockdown)—Data From Previous Survey, % ^a
1	7823	7202	8.6	-83.1
2	2975	3491	-14.8	-67.7
3	103	132	-22.0	-98.0
4	573	738	-22.4	-80.2
5	1013	1073	-5.6	-73.6
6	1109	1476	-24.9	-75.4
7	1990	2180	-8.7	-43.3
8	5399	8541	-36.8	-83.0
9	4296	7082	-39.3	-79.5
10	1134	2803	-59.5	-79.8
11	2641	2805	-5.8	-89.4
12	3386	5298	-36.1	-0.1
13	1392	1334	4.3	-70.0
14	1930	1478	30.6	-79.9
15	4551	7833	-41.9	-74.8
16	1377	1299	6.0	-10.2
17	147,362	209,068	-29.5	-65.6
18	1476	1376	7.27	-58.6
19	655	1105	-40.7	-70.0
20	28,041	24,075	16.5	-59.2
21	1416	1876	-24.5	-67.9
22	373	582	-35.9	-16.1
23	6004	8383	-28.4	-75.4
24	938	2212	-57.6	-71.6
25	364	425	-14.4	-65.4
26	1887	3695	-48.9	-99.8
27	3538	7049	-49.8	-88.5
28	1239	4514	-72.6	-89.5
29	1367	2341	-41.6	-84.7
Total	236,352	321,466	-26.5	-64.6

^aFor the previous survey, see Vigliar et al.⁸

TABLE 2. Overall Cytological Sample Workload During the 12-Week Post-Lockdown Period Compared With the Corresponding Period in 2019

	Total Samples		
	Post-Lockdown Period (2020), N°.	Corresponding Period (2019), N°.	Difference, %
Period I	49,724	82,720	-39.9
Period II	60,882	88,744	-31.4
Period III	60,715	77,917	-22.1
Period IV	65,031	72,085	-9.8
Total	236,352	321,466	-26.5

The data are grouped into four 3-week periods.

increase in comparison with the corresponding period in 2019 (12,442 [5.26%] vs 12,882 [4.01%]; $P < .001$). Similar results were obtained when malignant and suspicious for malignancy samples were considered together (15,759 [6.58%] vs 16,011 [4.98%]; $P < .001$). With respect to the malignancy and malignant and suspicious rates, in 2 cases, data were reported merged for all 4 analyzed periods. Overall, among the 27 respondent laboratories, the malignancy rate and the malignant and suspicious rate during the COVID-19 post-lockdown period (2020)

were higher in all examined periods in comparison with the corresponding period in 2019 (Table 4). Notably, the highest values were observed in period I (Table 4).

DISCUSSION

To the best of our knowledge, this is the first international, multicenter study to evaluate the cytopathological laboratory practices around the world during the immediate post-lockdown period. Notably, an overall reduction of processed cytological samples (26.5%) was observed between the post-lockdown period in 2020 and the corresponding period in 2019, with differences ranging from -72.6% to +30.6%. The absolute reduction in the number of processed specimens is alarming because of the increased risk for delayed treatment of patients with cancer. Only 4 specimen categories (central nervous system, gastrointestinal tract, biliary tract, and bone marrow specimens) did not show a decrease in the number of processed cytological samples in comparison with the prepandemic baseline. Overall, the highest reduction in samples was reported during the first 6 weeks in the post-lockdown period

TABLE 3. Overall Numbers and Proportions of Samples From Each Body Site During the Post-Lockdown Period and the Corresponding Period in 2019

Site	Overall Numbers			Difference Observed During Emergency Period (Lockdown)—Data From Previous Survey, % ^a
	Post-Lockdown Period (2020), N°.	Corresponding Period (2019), N°.	Difference, %	
Cervicovaginal tract	162,381	234,234	-30.7	-87.5
Urinary tract	18,712	20,916	-10.5	-53.5
Serous cavities	9701	11,659	-16.8	-33.6
Breast	4467	5642	-20.8	-57.1
Lymph node	9377	10,136	-7.5	-37.1
Thyroid	8954	13,328	-32.8	-80.5
Respiratory tract	11,143	12,693	-12.2	-50.7
Salivary gland	1315	1537	-14.4	-57.2
Soft tissue	770	894	-13.9	-59.6
Central nervous system	2532	2345	7.9	-30.1
Gastrointestinal tract	438	379	15.6	-51.6
Pancreas	1179	1268	-7.0	-23.5
Liver	367	434	-15.4	-3.3
Biliary tract	815	797	2.3	-42.6
Anal-rectal region	525	1004	-47.7	-98.7
Bone marrow	923	757	21.9	-81.4
Other sites	2753	3443	-20.0	-85.4
Total	236,352	321,466		

^aThe data come from the 29 respondents who participated in both surveys. For the previous survey, see Vigliar et al.⁸

TABLE 4. Malignancy Rates and Malignant and Suspicious Rates During the COVID-19 Post-Lockdown Period and the Corresponding Period in 2019 Grouped Into 4 Consecutive 3-Week Periods

	Post-Lockdown Period (2020)		Corresponding Period (2019)	
	Malignancy Rate	Malignant and Suspicious Rate	Malignancy Rate	Malignant and Suspicious Rate
Period I	5.7	7.4	3.5	3.5
Period II	5.0	6.4	3.6	3.6
Period III	4.9	6.3	4.0	4.0
Period IV	4.8	6.0	4.2	4.2

Abbreviation: COVID-19, coronavirus disease 2019.

The volume resulted from 27 respondents who provided data for each period.

(period I, -39.9%; period II, -31.4%) in comparison with the other 6 examined weeks (period III, -22.1%; period IV, -9.8; Table 2). Interestingly, other than different values of the overall reduction in cytology volume from each body site, different trends were observed in cytology practice recovery (Fig. 2). For example, Papanicolaou smears and thyroid samples showed a slow return to pre-COVID-19 levels; a possible explanation for the persistent reduction in the number of processed samples, particularly during the first 6 weeks of the post-lockdown period, may be the gradual reactivation of screening programs. Conversely, samples at high oncological risk, such as lymph node, breast, and respiratory tract fine-needle aspirates and serous fluids, showed a faster tendency to recover to pre-COVID-19 practice levels, as evident in the immediate post-lockdown period (period I or II); moreover, a steady

trend during the subsequent periods was observed. This phenomenon probably reflected the attitudes of clinicians and cytopathologists for prioritizing specific specimen types. A fluctuating trend, with only a slight reduction in comparison with the pre-COVID-19 era (2019), was finally observed for sites such as the soft tissue, central nervous system, liver, pancreas, and gastrointestinal and biliary tract; however, the low volumes analyzed probably do not enable distinctive kinetics to be demonstrated. Overall, for the majority of sample types, there seemed to be quite significant variation from the lockdown time period to period I and the post-lockdown period (2020; Fig. 2 and Tables 2 and 3).

As for the malignancy rate and the malignant and suspicious rate during the COVID-19 post-lockdown period, a higher value in all examined periods was observed

in comparison with the corresponding period in 2019 (Table 4). Notably, the highest values were observed in period I (Table 4).

Despite the interesting results, several limitations affect our article. First of all, the number of participants was limited with respect to the previous survey. Second, more than half of the examined cases belonged to a single institution (laboratory #17). However, even without this laboratory, an overall reduction of 20.8% (88,990 vs 112,398) was observed. Similarly, there was a statistically significant increase (5.9% vs 5.1%; $P < .001$) in the overall malignancy rate and in the overall malignant and suspicious for malignancy sample rates when they were considered together (8.8% vs 7.2%; $P < .001$) in comparison with the corresponding period in 2019.

In conclusion, the COVID-19 pandemic era was characterized by decreases and delays in identifying new cancers.¹⁵⁻¹⁷ Data generated from the present international, multicenter study showed that the postponement

of “nonurgent” medical procedures was still observed during the post-lockdown period. Nonetheless, the policy of prioritizing high-risk patients has proven to be effective and should be pursued in the future, if necessary. In fact, when we consider the overall data, there was a significant increase in the malignancy rate between 2019 and 2020 when only malignant cases or when both malignant and suspicious for malignancy diagnoses were considered. These data strongly support the role of cytology in the diagnostic management of high-risk patients with cancer, even during this unprecedented health care emergency.^{18,19} However, despite these results, the continued reduction of processed cytological samples in the post-lockdown period, which is related to national health care system countermeasures and the persistent reluctance of patients to go to the hospital, represents a global health care issue and serves as an important reminder of the potential consequences that such national policy measures can have on individuals with cancer.



Figure 2. Line charts of the overall workload for each cytological sample type normalized on a per-week basis and including data points from the COVID-19 lockdown period from the previous survey and 4 consecutive post-lockdown (2020) periods (red line). Data are compared with the corresponding period in 2019 (green line). COVID-19 indicates coronavirus disease 2019.



Figure 2.

FUNDING SUPPORT

Supported by Monitoraggio ambientale, studio ed approfondimento della salute della popolazione residente in aree a rischio–In attuazione della D.G.R. Campania n.180/2019; POR Campania FESR 2014-2020 Progetto “Sviluppo di Approcci Terapeutici Innovativi per patologie Neoplastiche resistenti ai trattamenti (SATIN)” and Campania Region for the Investigation of the Molecular Biology of Thyroid Cancer (grant LR n.24 29/12/2005). The University of Texas MD Anderson Cancer Center is supported by the National Institutes of Health (grant P30 CA016672).

CONFLICT OF INTEREST DISCLOSURES

Elena Vigliar reports personal fees from Diaceutics and AstraZeneca outside the submitted work. Lukas Bubendorf reports personal fees from Janssen, Takeda, AstraZeneca, Bayer, and Boehringer Ingelheim, from Systems Oncology; and grants from Sanofi outside the submitted work. Reinhard Büttner reports belonging to advisory boards for and receiving lecture fees from BMS, MSD, Novartis, Roche, Lilly, AstraZeneca, Lumina, AbbVie, Amgen, Boehringer Ingelheim, Merck-Serono, Qiagen, and Pfizer outside the submitted work. Xiaoyin Sara Jiang reports having been a consultant for Leica and having belonged to an advisory panel for Roche. Umberto Malapelle reports personal fees from Diaceutics, AstraZeneca, Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, GSK, and Merck outside the submitted work. Spasenija Savic Prince reports personal fees from MSD, AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, and

Thermo Fisher Scientific outside the submitted work. Paul A. VanderLaan reports personal fees from Gala Therapeutics, Intuitive Surgical, and Galvanize Therapeutics outside the submitted work. Giancarlo Troncone reports personal fees from Roche, MSD, Pfizer, Boehringer Ingelheim, Eli Lilly, BMS, GSK, Menarini, AstraZeneca, Amgen, and Bayer outside the submitted work. The other authors made no disclosures.

AUTHOR CONTRIBUTIONS

Conceptualization: **Elena Vigliar, William C. Faquin, Martha Bishop Pitman, and Giancarlo Troncone.** Methodology: All authors. Software and formal analysis: **Elena Vigliar and Filippo Dello Iacovo.** Validation: All authors. Investigation: All authors. Resources: All authors. Data curation: All authors. Writing–original draft: **Elena Vigliar, Pasquale Pisapia, Filippo Dello Iacovo and Giancarlo Troncone.** Writing–review and editing: All authors. Visualization: All authors. Supervision: **Elena Vigliar, William C. Faquin, Martha Bishop Pitman, and Giancarlo Troncone.** Project administration: **Elena Vigliar, William C. Faquin, Martha Bishop Pitman, and Giancarlo Troncone.** Funding acquisition: **Giancarlo Troncone.**

REFERENCES

- Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. *Int J Antimicrob Agents.* 2020;55:105924.

2. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med.* 2020;382:727-733.
3. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. *Lancet.* 2020;395:470-473.
4. WHO director-general's opening remarks at the media briefing on COVID-19—11 March 2020. World Health Organization. Accessed July 12, 2021. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>
5. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University & Medicine. Accessed July 12, 2021. <https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6>
6. Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. *Ann Oncol.* 2020;31:553-555.
7. Bardelli A. Coronavirus lockdown: what I learnt when I shut my cancer lab in 48 hours. *Nature.* Published online March 19, 2020. doi:10.1038/d41586-020-00826-7
8. Vigliar E, Cepurnaite R, Alcaraz-Mateos E, et al. Global impact of the COVID-19 pandemic on cytopathology practice: results from an international survey of laboratories in 23 countries. *Cancer Cytopathol.* 2020;128:885-894.
9. Wang YH, Bychkov A, Chakrabarti I, et al. Impact of the COVID-19 pandemic on cytology practice: an international survey in the Asia-Pacific region. *Cancer Cytopathol.* 2020;128:895-904.
10. Rana C, Kumar S, Babu S, et al. Impact of ongoing COVID-19 pandemic on cytology: an institutional experience. *Diagn Cytopathol.* 2021;49:311-315.
11. de Pelsemaeker MC, Guiot Y, Vanderveken J, Galant C, Van Bockstal MR. The impact of the COVID-19 pandemic and the associated Belgian governmental measures on cancer screening, surgical pathology and cytopathology. *Pathobiology.* 2021;88:46-55.
12. Vigliar E, Iaccarino A, Bruzzese D, Malapelle U, Bellevicine C, Troncone G. Cytology in the time of coronavirus disease (COVID-19): an Italian perspective. *J Clin Pathol.* 2021;74:261-263.
13. Vigliar E, Cepurnaite R, Iaccarino A, et al. Cytopathology practice during the COVID-19 postlockdown: an Italian experience. *Cancer Cytopathol.* 2021;129:548-554.
14. Palladino R, Migliatico I, Sgariglia R, et al. Thyroid fine-needle aspiration trends before, during, and after the lockdown: what we have learned so far from the COVID-19 pandemic. *Endocrine.* 2021;71:20-25.
15. Mitchell EP. Declines in cancer screening during COVID-19 pandemic. *J Natl Med Assoc.* 2020;112:563-564.
16. Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. *JCO Clin Cancer Inform.* 2020;4:1059-1071.
17. Basu P, Alhomoud S, Taghavi K, Carvalho AL, Lucas E, Baussano I. Cancer screening in the coronavirus pandemic era: adjusting to a new situation. *JCO Glob Oncol.* 2021;7:416-424.
18. Pisapia P, Troncone G. The two sides of cytopathology during the COVID-19 health emergency: screening versus diagnosis. *Pathobiology.* Published online July 21, 2020. doi:10.1159/000509958
19. Vose JM. Delay in cancer screening and diagnosis during the COVID-19 pandemic: what is the cost? *Oncology (Williston Park).* 2020;34:343.